Kodiak Sciences/$KOD

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Kodiak Sciences

Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.

Ticker

$KOD
Sector
Primary listing

Employees

121

Kodiak Sciences Metrics

BasicAdvanced
$488M
-
-$3.79
2.42
-

What the Analysts think about Kodiak Sciences

Analyst ratings (Buy, Hold, Sell) for Kodiak Sciences stock.

Bulls say / Bears say

Kodiak finished Q2 2025 with $104.2 million in cash and equivalents, enough to fund operations into 2026 as it advances clinical development (Reuters).
The company has completed commercial-scale batches at its URSUS manufacturing site ahead of planned BLA submissions, showcasing advanced manufacturing readiness (Reuters).
R&D spending grew in Q2 driven by active Phase 3 trials for tarcocimab, KSI-501, and KSI-101—underscoring the strong momentum in its late-stage pipeline (Reuters).
Net loss in Q2 2025 widened to $54.3 million, falling short of analyst estimates and highlighting persistently high cash burn (Reuters).
With Q2 operating expenses of $55.51 million versus a $104.2 million cash balance, Kodiak may need to secure more financing before it receives results from key trials, in order to keep its development programs running (Reuters).
Kodiak is still pre-commercial with no product revenues, and Wall Street’s median 12-month price target of $3.50 points to limited potential upside at current prices (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.

Kodiak Sciences Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Kodiak Sciences Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $KOD

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs